American Journal of Hypertension 1994-07-01

Experimental and clinical effects of isradipine relevant to atherosclerosis.

F Bernini, M R Soma, A Corsini, R Paoletti

Index: Am. J. Hypertens. 7(7 Pt 2) , 30S-34S, (1994)

Full Text: HTML

Abstract

A number of studies in experimental animal models have demonstrated the potential direct antiatherosclerotic effects of calcium antagonists. This class of compounds can influence several processes that are involved in the development of atherosclerotic lesions. This action is independent of either blood pressure reduction or hypercholesterolemia. A major problem encountered from the experimental data are the high doses used, which are several times higher than those used in the treatment of humans. One notable exception to this problem is the second-generation calcium antagonist isradipine, which exerts a direct antiatherosclerotic effect in rabbits at doses similar to those used in the clinic. Thus, this review is a summary of the effects and mechanisms of the antiatherosclerotic activity of isradipine.

Related Compounds

  • Isradipine

Related Articles:

Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons.

2014-08-01

[Brain 137(Pt 8) , 2287-302, (2014)]

Analysis of responses to the TRPV4 agonist GSK1016790A in the pulmonary vascular bed of the intact-chest rat.

2014-01-01

[Am. J. Physiol. Heart Circ. Physiol. 306(1) , H33-40, (2014)]

L-type calcium channel blockade alleviates molecular and reversal spatial learning and memory alterations induced by entorhinal amyloid pathology in rats.

2013-01-15

[Behav. Brain Res. 237 , 190-9, (2013)]

Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension.

1993-04-01

[Clin. Pharm. 12(4) , 261-75, (1993)]

Antiatherosclerotic actions of isradipine.

1992-01-01

[J. Cardiovasc. Pharmacol. 19 Suppl 3 , S29-31, (1992)]

More Articles...